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Background: Animal and human studies have implicated an imbalance of matrix
metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in
the pathogenesis of chronic obstructive pulmonary disease (COPD). MMP-9 protein is
increased in COPD and we hypothesized that total MMP activity would be raised although
this has not previously been measured.
Methods: Using fluorescence and biotin labelled MMP assays, RT-PCR, western blotting and
enzyme-linked immunosorbent assay we examined total MMP activity, specific gelatinase,
elastase, collagenase activity, TIMP-1 and TIMP-2 in induced sputum from smokers with
COPD and smokers without COPD.
Results: Induced sputum was obtained from 15 smokers with COPD and 14 smokers
without COPD. MMP-9 levels were higher in those with COPD compared with controls
(po0.05). Total MMP activity, specific gelatinase, collagenase and elastase activities were
not higher in COPD patients. In addition, reduced MMP activity was correlated with
increasing airflow obstruction in COPD (p ¼ 0.016).
Conclusion: MMP-9 protein but not MMP activity was higher in sputum of COPD patients
compared with controls. These results suggest that MMP-9 levels may not reflect the
overall MMP activity in the airways of patients with COPD suggesting a complex relationship
between MMP-9 protein and activity. Further studies of MMPs in COPD should comprise
activity measures in addition to protein levels.
& 2008 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Chronic obstructive pulmonary disease (COPD) is a major
cause of morbidity and mortality with 75% of cases
attributable to smoking.1 The protease–antiprotease hy-
pothesis has dominated thinking about COPD since the
observation that individuals with a hereditary deficiency of
the protein alpha-1 antitrypsin were at increased risk of
developing emphysema.2 Evidence from animal3–8 and hu-
man studies9–20 has implicated an imbalance of matrix
metalloproteinases (MMPs) and their natural inhibitors,
tissue inhibitors of matrix metalloproteinases (TIMPs), in
COPD pathogenesis.
MMPs are a family of structurally related metalloendo-
peptidases, which are crucial for the homeostasis and
turnover of the extracellular matrix both in health and
disease. MMP activity is tightly regulated at the level of gene
transcription, by proteolytic activation of the inactive
proenzymes and by inhibition of the active enzyme by TIMPs.
Studies have demonstrated increased levels of several
MMPs in lung tissue,9,12,15 bronchoalveolar lavage
(BAL)11,12,17,19,20 and induced sputum10,13,14,16,18 from pa-
tients with COPD. Many have shown that MMP-9 is increased
in the airways and lung parenchyma of patients with
COPD.11–20 These studies have estimated MMP activity either
from single MMP/TIMP ratios,11,16 by specific immunocapture
assays13 or zymography.11,12,14,17,19,20 We hypothesized that
the increase in MMP-9 protein would lead to an increase in
overall MMP activity in induced sputum from subjects with
COPD, and in contrast to previous studies, examined total
MMP activity using a quenched fluorescence assay which is
dependent on the total MMP/inhibitor balance.
Methods
Study subjects
The Nottingham Research Ethics Committee approved the
study. We recruited smokers with COPD defined by GOLD
criteria (COPD) and smokers without COPD (HS). Patients
were aged 40–80 years, had at least a 10-pack year smoking
history and had not required antibiotics or oral steroids for
the previous 6 weeks. Patients with a1-antitrypsin defi-
ciency, radiological evidence of interstitial lung disease,
previous thoracic surgery, or taking inhaled corticosteroids
were excluded. Spirometry was performed pre and post
bronchodilator according to American Thoracic Society
guidelines and breathlessness was recorded using the
Medical Research Council (MRC) dyspnoea score. Those with
reversibility greater than 10% of baseline FEV1 after inhaling
400mcg of salbutamol were excluded. Subjects with
FEV1/FVC of less than 70% were classified as having COPD.
Induced sputum samples were obtained from 15 current
smokers with COPD (COPD) and 14 current smokers without
COPD (HS).
Sputum induction and processing
Induced sputum was collected using previously described
techniques.21,22 The samples were divided into two por-
tions: one processed with 0.1% dithiothreitol (DL-Dithiothrei-tol, Sigma),22 the second sonicated. Differential cell counts
were performed according to standard methods.
Quenched fluorescence assay for total MMP activity
Total MMP activity was assessed directly by cleavage of the
quenched fluorescent substrate (Mca-Pro-Leu-Gly-Dpa-
Ala-Arg-NH2) (R&D Systems, UK) allowing simultaneous
measurement of the activity of MMP-1, MMP-2, MMP-7,
MMP-8, MMP-9, MMP-12 and MMP-13.24 DTT processed
sputum was used. To validate the assay for these samples
a linear relationship between fluorescence and concentra-
tion of activated recombinant MMP-9 was demonstrated in
the presence of DTT.
To ensure the specificity of the assay for MMPs, samples
from the HS and COPD groups were incubated with different
combinations of selective protease inhibitors. These were,
Ilomastat (Calbiochem, Merck Biosciences, Germany) a
specific MMP inhibitor, Complete Mini EDTA free Protease
Inhibitor Cocktail tablets (Roche Applied Science, Germany)
that inhibit serine, cysteine and acidic proteases but not
MMPs, and EDTA which inhibits proteins dependent upon
divalent cations including MMPs. Due to the volumes of
sample required these experiments were performed in BAL
fluid obtained from a different study.
Specific activity assays and immunoassay
Collagenase, gelatinase (Chemicon International, CA, USA)
and elastase (Molecular Probes, OR, USA) activities were
assessed in DTT processed sputum using specific assays. The
collagenase assay used bovine biotinylated collagen, which
was cleaved by active MMP-1, MMP-8 and MMP-13. The
gelatinase assay utilized a biotinylated gelatinase, which
was cleaved by active MMP-2 and MMP-9. The elastase assay
contains soluble bovine neck ligament elastin that has been
labelled with quenched fluorescence molecule. TIMP-1
protein was measured by ELISA (Amersham Bioscience, NJ,
USA).
RtPCR
TIMP-1 and TIMP-2 mRNA were detected in sputum cell
pellets by RtPCR. RNA was extracted from the stored cell
pellets using Qiagen RNA extraction kit (Qiagen, UK),
quantified and the purity checked using NanoDrops
ND-1000 UV–Vis spectrophotometer. cDNA synthesis was
undertaken using Protoscript cDNA synthesis kit (New England
Biolabs, MA, USA). PCR was performed using the following
primers: TIMP-1 forward AAGGCTCTGAAAAGGGCTTC, reverse
GAAAGATGGGCGTGGGAACA; TIMP-2 forward CCAAGCAGGAG-
TTTCTCGAC, reverse GACCCATGGGATGAGTGTTT. The pro-
ducts were run on 2% agarose gel and the bands were
sequenced to confirm the identity of the PCR products.
Western blot analysis
Expression of TIMP-1 and TIMP-2 protein was determined by
Western blot analysis. Membranes were blocked in 5% dry
milk plus unconjugated anti-human IgG (Vector Labs,
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Table 2 Concentrations and differentials of cells in
induced sputum in subjects with chronic obstructive
pulmonary disease (COPD) and smokers without COPD
(HS).
Reduced airway MMP activity in COPD 847Peterborough, UK) and incubated overnight at 4 1C with
monoclonal TIMP-1 (1:200 dilution) and monoclonal TIMP-2
(1:20 dilution) antibodies (Oncogene, Merck Biosciences,
Germany). Recombinant TIMP-1 and TIMP-2 were used as
controls (Oncogene, Merck Biosciences, Germany).COPD HS
Subjects, (n) 15 14
Weight of selected sputum (g) 0.7 (0.65) 0.46 (0.37)
TCC (106 cells g1) 2.25 (2.46) 2.8 (2.77)
Squamous cells (%) 3.9 (4.55) 2 (3.18)
Nonsq. epith. (%) 0.7 (0.6) 0.75 (0.68)
Macrophages (%) 24 (18) 28.5 (10.5)
Neutrophils (%) 73 (25) 69 (12.75)Zymography
Supernatants from induced sputum processed by sonication
were electrophoresed using pre-cast zymogram gels (Invi-
trogen, Carlsbad, CA, USA) and processed according to the
manufacturers guidelines. Bands were quantified by Gene-
tools Software (Syngene, UK).Lymphocytes (%) 0.6 (0.75) 0.5 (0.36)
Eosinophils (%) 0.5 (0.64) 0.5 (1.45)
Data presented as median (IQR). TCC: total cell count; nonsq.
epith.: nonsquamous epithelial cell.




Comparison by group was made using one-way ANOVAs (if
normally distributed) or paired t-test. A log transformation
was used to normalize the positively skewed distribution of
total MMP activity, and thus allow adjustment for age and
pack years in linear regression models. Correlations were
evaluated using the Pearson product–moment correlation.
All analyses were performed in SPSS (version 12.0.1 for
windows, SPSS Inc., IL, USA). po0.05 was considered




















Patients with COPD had mild to severe airflow obstruction,
whereas HS had, by definition, normal FEV1 and FEV1/FVC
ratio470. Those with COPD were older and had smoked
more than the HS group (Table 1). No significant differences
in sputum differential cell counts were found between the
two groups (Table 2).0.5
HS COPD
M
Figure 1 Gelatin zymography of sonicated sputum. Zones of
negative staining indicating enzymic activity. rMMP-9 ¼
recombinant activated MMP-9. MMP-9 band volume, derived
from zymography, in induced sputum obtained from smokers
with COPD (COPD) and smokers without COPD (HS). Solid
line ¼ mean value; *po0.05 vs. HS.MMP-9 levels in induced sputum and BAL
We examined MMP-9 protein in induced sputum using
zymography to confirm findings previously published.10,13,14
The MMP-9 band volume was significantly greater in the
COPD patients as compared to the HS (Figure 1).Table 1 Characteristics of study group.
Age Gender FEV1 (%predicted) FEV1/FVC Pack years MRC score Smoking status
M F Current Ex-smoker
Median (IQR)
COPD (n ¼ 15) 62* (16.5) 12 3 64* (43) 58* (20) 50* (28) 2.5 (2.25) 15 0
HS (n ¼ 14) 49 (15) 9 5 90.5 (22.75) 74 (6.5) 38 (16.5) 2 (1) 14 0
*po0.05 for comparison of COPD group (COPD) with smokers without COPD (HS).
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and BAL
To test the specificity of the assay for MMP activity we
examined the effect of MMP inhibitors on the activity of
recombinant MMP proteins and patient samples. These
experiments were performed in BAL from another study
due to the quantity of sample required. Ilomastat and EDTA
strongly inhibited the activity of recombinant MMP-9. EDTA




































0 100 200 300 400
Concentration of Ilomastat (mM)
MMP-9 MMP-3 MMP-2
no inhibitor 10mM 50mM
100mM 200mM 400mM
No inhibitor Ilomastat
Complete mini ED TA-free PI EDTA
Figure 2 (a) The effect of protease inhibitors on MMP activity
in BAL samples. Error bars denote standard deviations,
**po0.001. (b) Effect of increasing concentrations of Ilomastat
(a specific MMP inhibitor) on the activity measured in BAL from
COPD subjects (E) and smokers without COPD (&). (c) Effect
of Ilomastat on the activity measured due to recombinant
proteins MMP-9, MMP-3 and MMP-2.did not (Figure 2a). Complete mini EDTA-free protease
inhibitor tablets did not reduce activity in either case
suggesting the assay was detecting only metalloproteinase
activity (Figure 2a). Further experiments showed that
ilomastat inhibited activity in a dose-dependent manner in
BAL from healthy smokers and from COPD (Figure 2b). To
investigate why ilomastat did not fully inhibit BAL proteo-
lytic activity we examined the effect of ilomastat on
recombinant MMP-2, MMP-9 and MMP-3 in the assay. As
would be expected from the inhibition constants (Ki) of the
inhibitor for these substrates, ilomastat strongly inhibited
MMP-2 and MMP-9 and less strongly MMP-3 (Figure 2c).Total MMP activity
Surprisingly total MMP activity, measured using the quench
fluorescence assay, was equal in the COPD and HS groups
(Figure 3a), and although not significant there was a trend
towards lower MMP activity in those with the disease.
Worsening airflow obstruction, measured by FEV1/FVC ratio,
was associated with lower MMP activity (p ¼ 0.016,
Figure 3b). Furthermore there appeared to be a trend
towards lower MMP activity with increasing breathlessness
as judged by MRC dyspnoea score (Figure 3c). To test for
confounding by unequal sample concentration during the
sputum induction we adjusted all the samples to the same
protein concentration. The relationship between FEV1/FVC
ratio and total MMP activity persisted after protein correc-
tion (p ¼ 0.008). In addition, mean total MMP activity was
significantly lower in COPD patients after protein correction
(p ¼ 0.03). Lower total MMP activity was also associated
with lower FEV1 (p ¼ 0.05) and higher MRC dyspnoea score
(p ¼ 0.025).Collagenase, elastase and gelatinase activity
To further explore the finding of the quenched fluorescence
assay, we used three independent MMP activity assays.
These assays examined different MMP substrate specificities
(collagenase, gelatinase and elastase) and therefore provide
an alternative method of measuring MMP activity. Sputum
collagenase, gelatinase and elastase activities were not
associated with the presence of COPD, FEV1, or FEV1/FVC
ratio (Figure 4).Assessment of TIMP-1 and TIMP-2 in induced sputum
A possible explanation for the reduced MMP activity despite
increased MMP-9 protein as seen in those with COPD is an
increase in MMP inhibitors. As previous data suggested TIMP-
1 is raised in COPD subjects,10,13 we examined TIMP-1 and
TIMP-2 mRNA and protein in our samples. RNA was extracted
from induced sputum from 6 COPD subjects and 8 HS. RtPCR
for TIMP-1 and TIMP-2 were positive in all samples tested.
Western blotting showed TIMP-1 protein was present
in sputum samples, TIMP-2 protein was not detected
(Figure 5). To quantitatively examine TIMP-1 expression we
used an ELISA. No association was found between the levels
of TIMP-1 and FEV1, FEV1/FVC or MMP activity.
ARTICLE IN PRESS
Figure 3 Total MMP activity measured using the quenched fluorescence assay in sputum related to the disease status, MRC dyspnoea
score and FEV1/FVC: (a) ANOVA comparing MMP activity in COPD and healthy smokers (HS) (NS ¼ not significant). (b) Association of
FEV1/FVC and total MMP activity, p ¼ 0.016. (c) Trend relationship between disease severity assessed using the MRC breathlessness
score and total MMP activity.
Figure 4 Collagenase, gelatinase and elastase activity in induced sputum in smokers without COPD (HS) and smokers with COPD





Figure 5 Western blot of induced sputum supernatant to identify (a) TIMP-1 and (b) TIMP-2 proteins. Blots were exposed for 15min
without any evidence of an appropriate size band that would be consistent with TIMP-2.
Reduced airway MMP activity in COPD 849Discussion
Consistent with other studies we found higher levels of MMP-
9 protein associated with COPD,13,14 but surprisingly found
no significant difference in total MMP activity between
smokers with COPD and smokers without COPD. Indeed there
was a trend toward lower MMP activity in COPD and a
significant negative correlation between total MMP activity
and the degree of airflow obstruction.
Previous studies have shown increased levels of individual
MMPs in patients with COPD.10,11,13,14,16,17 However, MMP
protein levels do not directly reflect MMP activity as only the
inactive form of the protein may be present, or an excess of
an inhibitor may block activity. The experimental methods
used in some studies may separate the protease from the
inhibitor or may not take into account the amount of proteinin the active form. Our study adds to the previously
published work by using a quenched fluorescence substrate
that is only cleaved by activated MMPs and does not measure
pro-MMPs or those complexed with an inhibitor,24 thus
providing a direct measure of the biological activity of
metalloproteinases in the airways. Consistent with our
observations, specific gelatinase, collagenase and elastase
activities also showed no increase in MMP activity in COPD.
Experiments were performed to confirm that the proteo-
lytic activity measured by the quench fluorescent assay was
due to MMPs. The activity measured was unaffected by
serine, cysteine and acidic protease inhibitors, but inhibited
completely by the metal chelator EDTA suggesting that the
activity is due to metalloproteinases. Activity was reduced
with increasing concentrations of Ilomastat, a specific MMP
inhibitor. The response to Ilomastat was dose dependent and
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to be less sensitive to ilomastat than MMP-2 or MMP-9, in
keeping with the higher Ki of ilomastat for MMP-3 compared
with those of MMP-2 and MMP-9. However, some activity
remained even at high concentrations of Ilomastat raising
the possibility that other calcium- or zinc-dependent
proteases, such as the ADAMs (a disintegrin and metallopro-
teinase), ADAMTSs (a disintegrin and metalloproteinase with
a thrombospondin domain) or other uncharacterized metal-
loproteinase may be contributing to some of the activity
measured. The activity of an uncharacterized metallopro-
teinase is in keeping with our observation that gelatinase,
collagenase and elastase activities were not different
between the two groups.
Our findings that total MMP activity measured using the
quenched fluorescence assay was not raised in sputum of
COPD patients compared with HS and that lower total MMP
activity was associated with increasing airflow obstruction
(FEV1/FVC) (p ¼ 0.016) are surprising in light of previous
studies. Several important differences between our and
other studies may be responsible. Firstly, the global MMP
activity assay has not, to our knowledge, been used in
sputum from COPD patients and may detect the metallo-
protease activity of enzymes not measured by specific ELISA
or specific activity assay in other studies; for example due to
reduced activity of a previously uncharacterized metallo-
proteinase, including an ADAM or ADAM-TS protein. Sec-
ondly, in contrast to some other studies, we studied smoking
controls without COPD rather than non-smokers to eliminate
the effect of smoking. Smoking, in addition to COPD, is likely
to affect MMP activity as smoking results in increased airway
neutrophils, a source of MMPs including MMP-9.
There are several potential mechanisms which could
account for the discrepancy between protein expression and
activity we observed; namely an increase in MMP inhibitors,
reduced MMP activation, reduced activity of a previously
uncharacterized metalloproteinase in COPD or activation
MMPs at a specific time or site (such as the cell surface) not
sampled in our study.
The presence of increased MMP inhibitors in COPD is
possible. Previous studies have demonstrated that TIMP-1
protein was inversely correlated with reduced FEV1 in
COPD.14,16 Although it has been suggested that the balance
between protease–antiprotease is shifted toward increased
proteolytic activity on the basis of elevated levels of MMP-9
in COPD,10,13 in studies that have analysed the MMP-9/TIMP-
1 molar ratio it has been found that the balance is toward
the antiprotease.14,16 Although other studies have shown
higher levels of TIMP-1 in COPD compared to non-smoking
controls our data did not show any significant relationship
between TIMP-1 and smokers with and without COPD. In
addition we were unable to detect significant TIMP-2 protein
in our samples. The lower total MMP activity could still be
explained by increased levels of other inhibitors not
investigated as part of this study, for example TIMP-3 and
TIMP-4.
Another potential explanation for our findings is reduced
activation of MMPs in stable COPD. A study by Mercer et al.
investigated MMP-9/TIMP-1 balance in stable disease and
during exacerbations. They reported the MMP-9/TIMP-1
balance in favour of TIMP-1 in stable COPD, however, they
found elevated levels of MMP-9 in the sputum of COPDsubjects during exacerbations, shifting the balance between
MMP-9 and TIMP-1 in favour of MMP-9.27 They suggested that
there might be a shift between a ‘‘proteolytic’’ phenotype
during an exacerbation and a ‘‘fibrotic’’ phenotype outside
an exacerbation with the shift between ‘‘fibrotic’’ and
‘‘proteolytic’’ phenotypes contributing to the airway remo-
delling seen in COPD. Because the quenched fluorescence
assay measures the dynamic balance between activated
MMP and TIMP this could explain our findings and may
reconcile it with other studies which have showed increased
MMP and TIMP levels individually.
In summary, we have examined MMP activity by a variety
of methods in induced sputum in patients with stable COPD
and smokers without COPD. Despite increased MMP-9
protein, total MMP activity was not higher in sputum from
COPD subjects. These findings may reflect raised levels of
MMP inhibitors or a reduction in the activation of MMPs
during stable disease, however, we have not been able to
demonstrate this in the current study. Our findings suggest
that the activity of MMPs in COPD may be more complex
than previously thought and that the balance between MMPs
and TIMPs, the course of disease including exacerbations,
site of MMP activity and the overall effect on proteolytic
activity needs to be considered when investigating airway
inflammation.Conflict of interest statement
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